Capricor Therapeutics, Inc. · 1 day ago
Scientist, In Vitro Assay Development & Drug Substance Delivery
San Diego, CA
Full-time
Onsite
New Grad, Entry, Mid Level
$97K/yr - $129K/yr
0+ years expCapricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. They are seeking a highly motivated Scientist with deep expertise in in vitro assay development to support their therapeutic programs, focusing on designing, developing, and executing cellular assays for exosome-based delivery of therapeutic agents.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Design, develop, and validate mechanism‑of‑action and functional in vitro assays to assess therapeutic efficacy, potency, and safety
Establish PK/PD assay platforms to characterize cellular uptake, expression, and downstream biological responses
Utilize a range of assay technologies including high‑content imaging, flow cytometry, qPCR, Western blotting, and ELISA
Develop and optimize exosome or lipid nanoparticle loading and delivery protocols for protein, mRNA, siRNA, ASO, and PMO payloads
Characterize loading efficiency, payload integrity, delivery kinetics, and functional outcomes in vitro
Culture and manipulate diverse mammalian cells including primary cells, immortalized lines, and iPSCs
Perform transfection, transduction, and nucleic acid delivery followed by molecular and functional analyses
Support CRISPR/Cas9 or related gene editing workflows
Develop and apply disease‑relevant in vitro models for rare muscle disorders, including iPSC‑derived myoblasts
Correlate cellular phenotypes with disease‑relevant biomarkers and therapeutic mechanisms
Troubleshoot and optimize complex assay workflows and delivery methodologies
Analyze and interpret data; prepare clear presentations and written reports
Maintain rigorous documentation and data integrity standards
Work collaboratively with research, bioanalytics, and translational teams to align assay strategies with program objectives
Stay current with emerging technologies in drug delivery, nucleic acid therapeutics, assay platforms, and exosome science and apply innovative thinking to accelerate discovery
Qualification
Required
Ph.D. in Cell Biology, Molecular Biology, Biochemistry, or a related field with 0–3+ years of postdoctoral or industry experience; or M.S. with 5+ years of relevant experience
Proven hands‑on experience in in vitro assay design, development, and validation for therapeutic evaluation
Proficiency with mammalian cell culture, including primary cells, immortalized lines, and (ideally) iPSCs
Experience with exosome‑based or related drug substance delivery platforms (e.g., lipid nanoparticles) for protein, mRNA, siRNA, ASO, or PMO payloads
Technical capability with high‑content imaging, flow cytometry, qPCR, Western blotting, ELISA, and related analytical methods
Experience performing transfection, transduction, nucleic acid delivery, and subsequent molecular/functional analyses
Understanding of CRISPR/Cas9 genome engineering and, ideally, iPSC genome editing and differentiation into myogenic lineages such as myoblasts
Familiarity with rare muscle disease biology, associated cellular phenotypes, and relevant biomarkers
Working knowledge of nucleic acid and protein‑based therapeutic modalities including siRNA, ASO, PMO, mRNA, and proteins
Strong analytical skills with proficiency in data analysis tools such as GraphPad Prism and FlowJo
Demonstrated ability to troubleshoot complex biological systems and optimize experimental workflows
Highly organized with strong attention to detail and excellent documentation practices
Effective verbal and written communication skills; proven ability to work collaboratively across cross‑functional teams
Preferred
Experience with iPSC genome editing and differentiation into myogenic lineages is highly desirable
Company
Capricor Therapeutics, Inc.
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives.
51-200 employees
H1B Sponsorship
Capricor Therapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2021 (2)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$329.5MKey Investors
Nippon ShinyakuNational Institutes of HealthCalifornia Institute for Regenerative Medicine
2025-12-05Post Ipo Equity· $150M
2024-10-17Post Ipo Equity· $75M
2024-09-17Post Ipo Equity· $15M
Leadership Team
AJ Bergmann
Chief Financial Officer
Recent News
MarketScreener
2025-12-17
Genetic Engineering News
2025-12-09
Company data provided by crunchbase